/
PHAT
$10.87+$0.15 (+1.40%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$855.0M
80M shares
52-week range
$7.61 – $18.31
30% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-22.98
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $682.0K | $55.3M | $175.1M |
| Cost of revenue | $0 | $8.0K | $300.0K | $521.0K | $620.0K | $167.0K | $8.0M | $22.6M |
| Gross profit | $0 | −$8.0K | −$300.0K | −$521.0K | −$620.0K | $515.0K | $47.3M | $152.5M |
| Gross margin | — | — | — | — | — | 75.5% | 85.6% | 87.1% |
| R&D | $20.0K | $99.3M | $98.1M | $72.3M | $71.4M | $49.9M | $34.1M | $32.8M |
| Operating income | −$1.2M | −$106.2M | −$125.7M | −$135.1M | −$172.4M | −$167.3M | −$277.5M | −$160.0M |
| EBITDA | −$50.0K | −$250.9M | −$124.2M | −$136.6M | −$169.8M | −$159.0M | −$261.5M | −$152.5M |
| Net income | −$1.3M | −$209.7M | −$129.1M | −$143.9M | −$197.7M | −$201.6M | −$334.3M | −$221.2M |
| Net margin | — | — | — | — | — | -29558.9% | -605.1% | -126.3% |
| EPS (diluted) | -0.15 | -8.48 | -4.01 | -4.00 | -5.70 | -3.93 | -5.29 | -3.03 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $334M | $-0.62 | $-0.69–$-0.60 | 3 |
| 2027 | $540M | $1.19 | $1.14–$1.32 | 3 |
| 2028 | $755M | $2.72 | $1.74–$5.02 | 7 |
| 2029 | $905M | $3.96 | $3.79–$4.37 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
www.phathompharma.com- Employees
- 371
- IPO / List date
- Oct 25, 2019
- HQ
- FLORHAM PARK, NJ
Held by traders on TradeandTell
No one on the platform currently holds PHAT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 305,800 | $3.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PHAT yet.
